Pegcantratinib clinical trials
Also written SNA-120 and CT 327.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses pegcantratinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses pegcantratinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With CalcipotrieneCompletedPhase 2Sienna BiopharmaceuticalsNCT03448081Written as SNA-120
- Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis VulgarisCompletedPhase 2Sienna BiopharmaceuticalsNCT03322137Written as SNA-120
- A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic DermatitisCompletedPhase 2Creabilis SANCT01808157Written as CT327 ointment
- Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis VulgarisCompletedPhase 2Creabilis SANCT01465282Written as CT327 0.05%
- CT 327 in the "Atopy Patch Test" ModelWithdrawnPhase 1Creabilis SANCT01368315Written as CT327 application
- CT 327 in the Treatment of Psoriasis VulgarisCompletedPhase 2Creabilis SANCT00995969Written as CT 327
- CT 327 in the Treatment of Atopic DermatitisTerminatedPhase 2Creabilis SANCT00996008Written as CT 327
Codes
What other systems call pegcantratinib · ClinicalTrials.gg INT000906
- UNII (FDA) VG44NU1168PEGCANTRATINIBOne source FDA
- NCI Thesaurus C170295PegcantratinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VG44NU1168 | PEGCANTRATINIB | One source FDA |
| NCI Thesaurus | C170295 | Pegcantratinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.